iPSC Lines, Human, Normal
Human induced pluripotent stem cell lines (hiPSCs) from cord blood cells, fibroblasts, and PBMCs for Disease modeling, Genome editing service, Neural differentiation panel, and Neurotoxicity screening. The control iPS lines are well characterized, and have been successfully used for genome editing and neural lineage differentiation projects.
Human induced Pluripotent Stem Cells (iPSCs) generated by episomal expression of reprogramming factors. We offer footprint-free human iPSC lines derived from human fibroblasts by ectopic expression of OCT4, SOX2, KLF4, and c-MYC genes using episomal plasmids. All induced pluripotent stem cell (iPSC) lines were derived using morphological selection criteria and without the use of fluorescent marker or drug selection. When cultured under standard human ES cell culture conditions, the morphology of human iPS cells is identical to that of human embryonic stem cells (ESC/ES cells). The cells also express the pluripotency markers SSEA-3 and Nanog and demonstrate strong endogenous alkaline phosphatase.
- Well characterized, footprint-free control iPSC lines from different tissue sources: See Technical Details
- These iPSCs have proven differentiation capability to neural lineage cells using easy and optimized protocols
- Suitable for genetic modification using CRISPR/Cas9 and TARGATT™: Neural Disease Specific KO iPSCs, Knock-in Reporter iPSC, and TARGATT Knock-in iPSC
- They serve as isogenic controls for engineered cell lines
- Multiple donors and tissue sources provide a broad genetic background for basic research, drug and toxicity screening applications
We also have a human control iPSC lines reprogrammed from fibroblasts using retroviral methods: ASE-9101
*Commercial use? Please contact us for licensing.
The male iPSC ASE-9109 was generated from fibroblasts obtained from a healthy, male neonate using retroviral reprogramming methods.
ASE-9109: Normal iPSC differentiation to cardiomyocytes
- Kavyasudha C., Macrin D., ArulJothi K.N., Joseph J.P., Harishankar M.K., Devi A. (2018) Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale. In: Advances in Experimental Medicine and Biology. Springer, New York, NY. https://doi.org/10.1007/5584_2018_173.
- Lin, Y., Linask, K. L., Mallon, B., Johnson, K., Klein, M., Beers, J., ... & Zou, J. (2017). Heparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin‐Free Medium, Enabling Consistent Manufacture of Cardiomyocytes. Stem cells translational medicine, 6(2), 527-538.
ASE-9208: Sporadic Parkinson’s disease line
- Hsieh, C. H., Shaltouki, A., Gonzalez, A. E., da Cruz, A. B., Burbulla, L. F., Lawrence, E. S., ... & Wang, X. (2016). Functional impairment in Miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson’s disease. Cell Stem Cell, 19(6), 709-724.
Human iPSCs: iPSCs from ALS8 patient and non-carrier siblings
- Mitne-Neto, M., Machado-Costa, M., Marchetto, M. C., Bengtson, M. H., Joazeiro, C. A., Tsuda, H., ... & Muotri, A. R. (2011). Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Human molecular genetics, 20(18), 3642-3652.
- Daily, N. J., et al. (2017). High-Throughput Phenotyping of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Neurons Using Electric Field Stimulation and High-Speed Fluorescence Imaging. ASSAY and Drug Development Technologies. 15(4): 178-188. https://doi.org/10.1089/adt.2017.781
- Daily, N. J., Santos, R., Vecchi, J., Kemanli, P., & Wakatsuki, T. (2017). Calcium transient assays for compound screening with human iPSC-derived cardiomyocytes: Evaluating new tools. Journal of evolving stem cell research, 1(2), 1.
- Daily, N. J., et al. (2015). Journal of Bioengineering & Biomedical Science, 2015.
Mouse/ Rat/ Pig/ Guinea Pig